Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15313032 | 0.88 | EPHX2 (0.77) | EPHX2EPHX1LMNAUSP2 | |
| SCHEMBL4016889 | 0.85 | EPHX2 (0.74) | EPHX2EPHX1LMNAUSP2 | |
| SCHEMBL4449239 | 0.85 | EPHX2 (0.74) | EPHX2EPHX1 | |
| SCHEMBL15313029 | 0.85 | EPHX2 (0.72) | EPHX2EPHX1LMNAUSP2 | |
| SCHEMBL4011987 | 0.84 | EPHX2 (0.73) | EPHX2EPHX1LMNA | |
| SCHEMBL13651413 | 0.82 | EPHX2 (0.74) | EPHX2EPHX1 | |
| SCHEMBL4017232 | 0.82 | EPHX2 (0.69) | EPHX2EPHX1LMNAUSP2 | |
| SCHEMBL4299897 | 0.81 | EPHX2 (0.67) | EPHX2EPHX1 | |
| SCHEMBL8048274 | 0.80 | EPHX1 (0.69) | EPHX2EPHX1LMNA | |
| Ar9281 SCHEMBL18464997 | 0.80 | EPHX2 (1.00) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029539-B1 | N-(piperidinyl)-urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of e.g. hypertension or inflammations | UNIV CALIFORNIA (US) | 2016-06-29 | — | — | EP | claimed |
| US-8501783-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-06 | — | — | US | claimed |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | claimed |
| US-8188289-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-29 | — | — | US | claimed |
| WO-2010053829-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. | 2010-03-11 | — | — | US | claimed |
| WO-2010025043-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | WO | claimed |
| EP-2124917-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | Arete Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | claimed |
| WO-2009129501-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | claimed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | claimed |
| EP-2077839-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | Arete Therapeutics, INC. (US) | 2009-07-15 | — | — | EP | claimed |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20080221104-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
| WO-2008094869-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2008058033-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | ARETE THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
| EP-2029539-B1 | N-(piperidinyl)-urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of e.g. hypertension or inflammations | UNIV CALIFORNIA (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2007106525-A1 | PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106525-A1 | PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | EPHX2 5/4885EPHX1 1/4885LMNA 2489/4885 |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | EPHX1, PTGIS, PDE3A | EPHX2 6/4885EPHX1 1/4885LMNA 2614/4885 |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ALOX15B, ALOX15, ALOX12 | EPHX2 6/4885EPHX1 7/4885LMNA 1688/4885 |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | EPHX2 6/4885EPHX1 1/4885LMNA 2686/4885 |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | EPHX2 6/4885EPHX1 1/4885LMNA 2686/4885 |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885LMNA 3843/4885 |
| US-20080221104-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | EPHX1, EPHX2, LTA4H | EPHX2 2/4885EPHX1 1/4885LMNA 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.